放射性药物DOTA-微型胃泌素类似物(CP04)配合物的结构研究及其与CCK2受体的相互作用
该研究探讨CP04与CCK-2R的结合亲和力是否受络合放射性金属种类影响,并通过分子建模解析CP04-CCK2R复合物结构。体外实验显示[68Ga]Ga3+与[177Lu]Lu3+络合的CP04在CCK-2R结合亲和力及特异性细胞摄取上无显著差异;同源建模与分子对接模型显示C端进入受体螺旋腔,N端及金属暴露于溶剂,放射性金属除螯合基团邻近区域外不影响分子构象。
要点
- 体外实验显示[68Ga]Ga3+与[177Lu]Lu3+络合的CP04在CCK-2R结合亲和力及特异性细胞摄取上无显著差异。
- 模型显示CP04的C端进入受体螺旋间腔,N端(含DOTA和金属)位于结合位点出口并大部分暴露于溶剂。
- 放射性金属除螯合部分直接邻近区域外不影响CP04构象,模型与部分构效关系及定点突变数据一致。
核心结论
- CP04对CCK-2R的结合亲和力对络合放射性金属种类相对不敏感,所提出的结合模型似乎与许多CCK和CCK-2R靶向放射性药物的构效关系研究一致,并部分符合已报道的定点突变数据。
研究设计与样本
- 体外研究结合同源建模与分子对接,提出CP04与CCK-2R的结合模型。
主要发现
- 体外研究证明[68Ga]Ga3+或[177Lu]Lu3+络合的CP04在CCK-2R结合亲和力和特异性细胞摄取上无显著差异。
- 模型中CP04的C端部分进入受体螺旋之间形成的腔,N端(包括DOTA和金属)位于结合位点出口并大部分暴露于溶剂。
- 放射性金属不影响分子构象,除非在螯合部分的直接邻近区域。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The cholecystokinin receptor subtype 2 (CCK-2R) is an important target for diagnostic imaging and targeted radionuclide therapy (TRNT) due to its overexpression in certain cancers (e.g., medullary thyroid carcinoma (MTC)), thus matching with a theranostic principle. Several peptide conjugates suitable for the TRNT of MTC have been synthesized, including a very promising minigastrin analogue DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 (CP04). In this contribution, we wanted to see whether CP04 binding affinity for CCK-2R is sensitive to the type of the complexed radiometal, as well as to get insights into the structure of CP04-CCK2R complex by molecular modeling. RESULTS: In vitro studies demonstrated that there is no significant difference in CCK-2R binding affinity and specific cellular uptake between the CP04 conjugates complexed with [68Ga]Ga3+ or [177Lu]Lu3+. In order to investigate the background of this observation, we proposed a binding model of CP04 with CCK-2R based on homology modeling and molecular docking. In this model, the C-terminal part of the molecule enters the cavity formed between the receptor helices, while the N-terminus (including DOTA and the metal) is located at the binding site outlet, exposed in large extent to the solvent. The radiometals do not influence the conformation of the molecule except for the direct neighborhood of the chelating moiety. CONCLUSIONS: The model seems to be in agreement with much of structure-activity relationship (SAR) studies reported for cholecystokinin and for CCK-2R-targeting radiopharmaceuticals. It also explains relative insensitivity of CCK-2R affinity for the change of the metal. The proposed model partially fits the reported site-directed mutagenesis data.
引用
- Lipiński PFJ, Garnuszek P, Maurin M, et al. Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor. EJNMMI Res. 2018. PMID: 29663167. doi:10.1186/s13550-018-0387-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。